These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25913120)

  • 1. Development and evaluation of a tampering resistant transdermal fentanyl patch.
    Cai B; Engqvist H; Bredenberg S
    Int J Pharm; 2015 Jul; 488(1-2):102-7. PubMed ID: 25913120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the resistance of a geopolymer-based drug delivery system to tampering.
    Cai B; Engqvist H; Bredenberg S
    Int J Pharm; 2014 Apr; 465(1-2):169-74. PubMed ID: 24556174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alghedon Fentanyl Transdermal System.
    Romualdi P; Santi P; Candeletti S
    Minerva Med; 2017 Apr; 108(2):169-175. PubMed ID: 27886163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Fentanyl Patch Boil-Up - A Novel Method of Opioid Abuse.
    Schauer CK; Shand JA; Reynolds TM
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):358-9. PubMed ID: 25892448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transdermal delivery of fentanyl.
    Lane ME
    Eur J Pharm Biopharm; 2013 Aug; 84(3):449-55. PubMed ID: 23419814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
    Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
    Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and in vitro evaluation of new drug-in-adhesive formulations of fentanyl transdermal patches.
    Mehdizadeh A; Toliate T; Rouini MR; Abashzadeh S; Dorkoosh F
    Acta Pharm; 2004 Dec; 54(4):301-17. PubMed ID: 15634614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
    Stanos SP; Bruckenthal P; Barkin RL
    Mayo Clin Proc; 2012 Jul; 87(7):683-94. PubMed ID: 22766088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
    Kress HG; Von der Laage D; Hoerauf KH; Nolte T; Heiskanen T; Petersen R; Lundorff L; Sabatowski R; Krenn H; Rosland JH; Saedder EA; Jensen NH
    J Pain Symptom Manage; 2008 Sep; 36(3):268-79. PubMed ID: 18538974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of Detachment and Clinical Usability of Transdermal Fentanyl Patches in Healthy Volunteers].
    Kurita K; Mochizuki Y; Kokubun H; Atsuta K
    Yakugaku Zasshi; 2015; 135(11):1307-15. PubMed ID: 26521880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of soluble fentanyl microneedles for loco-regional anti-nociceptive activity.
    Maurya A; Rangappa S; Bae J; Dhawan T; Ajjarapu SS; Murthy SN
    Int J Pharm; 2019 Jun; 564():485-491. PubMed ID: 31026490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicological implications of the delivery of fentanyl from gel extracted from a commercial transdermal reservoir patch.
    Oliveira G; Hadgraft J; Lane ME
    Toxicol In Vitro; 2012 Jun; 26(4):645-8. PubMed ID: 22405881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the fentanyl patch-for-patch program in Ontario, Canada.
    Tadrous M; Greaves S; Martins D; Nadeem K; Singh S; Mamdani MM; Juurlink DN; Gomes T
    Int J Drug Policy; 2019 Apr; 66():82-86. PubMed ID: 30743092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal fentanyl patch misuse in a hospitalized patient with a postmortem increase in fentanyl blood concentration.
    Moore PW; Palmer RB; Donovan JW
    J Forensic Sci; 2015 Jan; 60(1):243-6. PubMed ID: 25041753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of transdermal fentanyl patch attachment in dogs and analysis of residual fentanyl content following removal.
    Reed F; Burrow R; Poels KL; Godderis L; Veulemans HA; Mosing M
    Vet Anaesth Analg; 2011 Jul; 38(4):407-12. PubMed ID: 21672129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
    Botterman J; Criel N
    Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design.
    Roy SD; Gutierrez M; Flynn GL; Cleary GW
    J Pharm Sci; 1996 May; 85(5):491-5. PubMed ID: 8742940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the use of a transdermal fentanyl patch in cats.
    Scherk-Nixon M
    J Am Anim Hosp Assoc; 1996; 32(1):19-24. PubMed ID: 8963731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.